Medtronic has received the US Food and Drug Administration (FDA) approval for the Simplera Sync sensor to enhance the flexibility of its MiniMed 780G system.
The advanced insulin delivery system with meal detection technology can be used with both the Guardian 4 sensor and the newly approved Simplera Sync sensor.
The Simplera Sync is a disposable, all-in-one sensor that eliminates the need for fingersticks with SmartGuard or overtape.
It requires a simple, two-step insertion process that enhances convenience and expands Medtronic’s continuous glucose monitoring (CGM) portfolio to offer patients more options.
The MiniMed 780G system’s adaptive algorithm automatically adjusts and corrects glucose levels every five minutes, 24/7.
The technology helps maintain glucose levels within the target range, even when users occasionally forget to dose insulin for meals or snacks.
The system’s ‘treat to target’ approach and flexible glucose targets as low as 100 mg/dL aim to mirror the glucose levels of individuals without diabetes.
According to real-world data, the MiniMed 780G system users consistently achieved time in range above international targets of 70% when using optimal settings.
In addition, the system is compatible with an infusion set lasting up to seven days, reducing the frequency of injections compared to multiple daily injections.
The company plans a limited launch of the Simplera Sync sensor in the US this year.
Medtronic Diabetes president and executive vice president Que Dallara said: “We’re committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day.
“Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we’re excited to continue evolving this experience with expanded CGM options, including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the US.”
